The effect of GHRH, GHRP-2 and somatostatin on GH secretion by fetal pituitary.
Liu. Q Q; Bai. X X; Liu. K K; Lin. W W; Lei. T T
Key Findings
- GHRP-2 stimulates GH secretion in human fetal pituitary somatotroph cells.
- The peptide uses a membrane receptor distinct from GHRH and somatostatin receptors.
- The signaling pathway for GHRP-2 appears different from the classic GHRH/SST pathways.
Practical Outcomes
- For biohackers, the main takeaway is that GHRP-2 can boost growth hormone via its own receptor, supporting its use as a GH‑releasing agent. However, because the data come from fetal cell cultures, the findings don’t directly translate into dosing or safety guidelines for adult use, so it’s more of a mechanistic confirmation than a protocol upgrade.
Summary
The study shows that GHRP-2, a synthetic peptide, can trigger growth hormone release from fetal pituitary cells using a different receptor than the usual growth‑hormone‑releasing hormone (GHRH) or somatostatin pathways. This means GHRP-2 works through its own unique mechanism, but the research was done in cell cultures from fetal tissue, not in adults.
Abstract
Growth hormone releasing peptide (GHRP-2) is a synthetic hexapeptide which specifically stimulates secretion of growth hormone (GH) by fetal pituitary somatotrophs through a new membrane receptor, which is different from growth hormone releasing hormone (GHRH) and somatostatin (SMS) receptors. We used cell cultures of human fetal pituitary somatotroph cells to investigate the effect of GHRH, GHRP-2 and somatostatin on GH secretion. The results showed that the mechanism of GHRH/SMS and GHRP-2 was different. This indicated that a different intracellular signal transduction system might also play a crucial role in the regulation of GH secretion.
Study Information
pubmed
1999
10.1007/bf02886962